Collection of Samples and Clinical Data From Patients With Amyloid Diseases

Last updated: December 26, 2024
Sponsor: Boston Medical Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Multiple Myeloma

Leukemia

Lymphoproliferative Disorders

Treatment

protein analysis

clonality analysis

quality-of-life assessment

Clinical Study ID

NCT00898235
H-22838
CDR0000632869
  • Ages > 18
  • All Genders

Study Summary

RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future.

PURPOSE: This research study is collecting samples from patients with amyloid diseases

Eligibility Criteria

Inclusion

Inclusion Criteria:

DISEASE CHARACTERISTICS:

  • Diagnosis or suspicion of amyloidosis

PATIENT CHARACTERISTICS:

  • Referred to the Amyloid Treatment and Research Center at Boston University MedicalCenter

PRIOR CONCURRENT THERAPY:

  • Not specified

Exclusion

Exclusion Criteria:

None

Study Design

Total Participants: 10000
Treatment Group(s): 7
Primary Treatment: protein analysis
Phase:
Study Start date:
January 01, 2000
Estimated Completion Date:
December 31, 2040

Study Description

OBJECTIVES:

  • To establish and maintain a database of clinical material (i.e., blood, urine, and tissue) and information on patients with amyloid diseases.

OUTLINE: Blood, urine, tissue, and bone marrow samples are collected during standard laboratory evaluations to maintain a repository of biospecimens in the Gerry Amyloid Research Laboratory, to permit the correlation of clinical results with measured biological events, and for future research studies. Bone marrow RNA samples are examined for immunoglobulin light-chain gene sequences and amino acids by polymerase chain reaction and positional cloning. Blood serum and urine samples are evaluated for amyloid protein stability by high-resolution calorimetry, isothermal-titration calorimetry, and far- and near-UV circular dichroism and fluorescence spectroscopy. Urine samples are also examined for post-translational modifications (e.g., glycosylation, sulfation, and cross-linking) to identify common features unique to amyloid proteins. Tissue samples are analyzed for biochemical and biophysical properties and for post-translational modifications in light chains.

Quality of life is assessed by the 36-Item Short Form Survey (SF-36).

Connect with a study center

  • Boston University Cancer Research Center

    Boston, Massachusetts 02118
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.